Genetic rearrangement during site specific integration event facilitates cell line development of a bispecific molecule.

CHO cells bioprocess development gene expression system multi-specific molecule site-specific integration

Journal

Biotechnology progress
ISSN: 1520-6033
Titre abrégé: Biotechnol Prog
Pays: United States
ID NLM: 8506292

Informations de publication

Date de publication:
07 2021
Historique:
revised: 16 04 2021
received: 03 03 2021
accepted: 19 04 2021
pubmed: 24 4 2021
medline: 5 4 2022
entrez: 23 4 2021
Statut: ppublish

Résumé

Site specific integration (SSI) expression systems offer robust means of generating highly productive and stable cell lines for traditional monoclonal antibodies. As complex modalities such as antibody-like molecules comprised of greater than two peptides become more prevalent, greater emphasis needs to be placed on the ability to produce appreciable quantities of the correct product of interest (POI). The ability to screen several transcript stoichiometries could play a large role in ensuring high amounts of the correct POI. Here we illustrate implementation of an SSI expression system with a single site of integration for development and production of a multi-chain, bi-specific molecule. A SSI vector with a single copy of all of the genes of interest was initially selected for stable Chinese hamster ovary transfection. While the resulting transfection pools generated low levels of the desired heterodimer, utilizing an intensive clone screen strategy, we were able to identify clones having significantly higher levels of POI. In-depth genotypic characterization of clones having the desirable phenotype revealed that a duplication of the light chain within the landing pad was responsible for producing the intended molecule. Retrospective transfection pool analysis using a vector configuration mimicking the transgene configuration found in the clones, as well as other vector configurations, yielded more favorable results with respect to % POI. Overall, the study demonstrated that despite the theoretical static nature of the SSI expression system, enough heterogeneity existed to yield clones having significantly different transgene phenotypes/genotypes and support production of a complex multi-chain molecule.

Identifiants

pubmed: 33891804
doi: 10.1002/btpr.3158
pmc: PMC8459265
doi:

Substances chimiques

Recombinant Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3158

Informations de copyright

© 2021 Pfizer Inc. Biotechnology Progress published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.

Références

J Mol Biol. 2012 Jul 13;420(3):204-19
pubmed: 22543237
Mol Immunol. 2015 Oct;67(2 Pt A):95-106
pubmed: 25637431
Nat Rev Drug Discov. 2018 Mar;17(3):197-223
pubmed: 29192287
Comput Struct Biotechnol J. 2020 Nov 12;18:3632-3648
pubmed: 33304461
ACS Synth Biol. 2018 Sep 21;7(9):2148-2159
pubmed: 30060646
Biotechnol Prog. 2019 Jan;35(1):e2724
pubmed: 30299005
PLoS One. 2014 Oct 20;9(10):e110874
pubmed: 25329675
Curr Opin Biotechnol. 2000 Oct;11(5):455-60
pubmed: 11024363
Biotechnol Bioeng. 2017 Aug;114(8):1837-1846
pubmed: 28186334
Gene. 2013 Feb 15;515(1):1-27
pubmed: 23201421
Protein Eng. 1996 Jul;9(7):617-21
pubmed: 8844834
Biotechnol Bioeng. 2016 Nov;113(11):2518-23
pubmed: 27159230
Biotechnol Lett. 2019 Sep;41(8-9):941-950
pubmed: 31236787
Biotechnol Prog. 2021 Jul;37(4):e3137
pubmed: 33609084
Nucleic Acids Res. 2018 May 4;46(8):4072-4086
pubmed: 29617873
Appl Microbiol Biotechnol. 2018 Jul;102(14):6105-6117
pubmed: 29789882
Appl Microbiol Biotechnol. 2012 Feb;93(3):917-30
pubmed: 22159888
Nat Biotechnol. 2004 Nov;22(11):1393-8
pubmed: 15529164
Biotechnol Prog. 2015 Nov-Dec;31(6):1645-56
pubmed: 26399954
Proc Natl Acad Sci U S A. 1984 Nov;81(22):7185-8
pubmed: 6438634
Proc Natl Acad Sci U S A. 1980 Apr;77(4):2197-9
pubmed: 6769123
Biotechnol Adv. 2012 Sep-Oct;30(5):1158-70
pubmed: 21968146
MAbs. 2010 Sep-Oct;2(5):466-79
pubmed: 20622510
Biotechnol Bioeng. 2017 Nov;114(11):2616-2627
pubmed: 28734047
Biotechnol Prog. 2021 Jul;37(4):e3158
pubmed: 33891804
Front Immunol. 2017 Jan 26;8:38
pubmed: 28184223
Biotechnol Bioeng. 2019 Jan;116(1):41-53
pubmed: 30144379
J Microbiol Biotechnol. 2008 Jul;18(7):1342-51
pubmed: 18667865
MAbs. 2009 Sep-Oct;1(5):443-52
pubmed: 20065641
J Biotechnol. 2013 Jun 10;165(3-4):157-66
pubmed: 23583871
MAbs. 2017 Feb/Mar;9(2):182-212
pubmed: 28071970

Auteurs

Barbara Tevelev (B)

Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.

Himakshi Patel (H)

Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.

Kathleen Shields (K)

Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.

Wei Wei (W)

Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.

Cecilia Cooley (C)

Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.

Sam Zhang (S)

Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.

Gabrielle Bitzas (G)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Weili Duan (W)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Lam Khetemenee (L)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Ryan Jackobek (R)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Aaron D'Antona (A)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Annette Sievers (A)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Amy King (A)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Amy Tam (A)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Yan Zhang (Y)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Eric Sousa (E)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Justin Cohen (J)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Lila Wroblewska (L)

BioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.

Jeffrey Marshall (J)

Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.

Martha Jackson (M)

Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.

John J Scarcelli (JJ)

Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

Classifications MeSH